176637-10-8

Basic information

• Product Name: 8-Chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine
• Synonyms: 8-Chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine;4-Chloro-6-(methylthio)pyrimido[5,4-d]pyrimidine;8-chloro-2-(Methylsulfanyl)-[1,3]diazino[5,4-d]pyriMidine
• CAS NO: 176637-10-8
• Molecular Formula: C₇H₅ClN₄S
• Molecular Weight: 212.663
• Mol File: 176637-10-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 8-Chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine(176637-10-8)
• EPA Substance Registry System: 8-Chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine(176637-10-8)

Safety Data

• Hazardous Substances Data: 176637-10-8(Hazardous Substances Data)

Usage

General Description

8-Chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine is a synthetic chemical compound that belongs to the pyrimidine class. It is characterized by a pyrimidine ring system with a chlorine atom at position 8 and a methylthio group at position 2. 8-Chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine has potential applications in pharmaceutical research and drug development, as it may exhibit biological activity due to its structure. Further research and testing are needed to determine its specific properties and potential uses in various fields, including medicine and industry.

Upstream product

• 98550-19-7 4-hydroxy-6-methylthio-pyrimido[5,4-d]pyrimidine 

Downstream Products

• 1213249-80-9 C₁₆H₁₅N₅O₂S 
• 1213249-88-7 C₁₅H₁₃N₅O₂S 
• 1213249-79-6 C₂₃H₁₉F₃N₆O₂S 
• 1213250-28-2 C₂₇H₃₁N₇O₄S₂ 
• 1391916-05-4 C₁₆H₁₆F₂N₆O₂S₂ 
• 177908-24-6 4-[(3-Chloro-4-fluoro-phenyl)amino]-6-methylthio-pyrimido[5,4-d]pyrimidine 

Relevant articles and documents

SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

Pyrimido [5, 4-d] pyrimidines, pharmaceuticals containing these compounds, their use and processes for their preparation

Pyrimido[5,4-d]pyrimidines of the general formula [Figure] which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of oncoses, and their preparation. Exemplary compounds are: (a) 4-(5-indolylamino)-6-morpholinopyrimido[5,4-d]pyrimidine; (b) 4-(5-indolylamino)-6-[trans-(4-hydroxycyclohexyl)amino]pyrimido[5,4-d]pyrimidine; (c) 4-[(3-chloro-4-fluorophenyl)amino]-6-[4-(morpholinocarbonylmethyl)-1-piperazinyl]pyrimido[5,4-d]pyrimidine; (d) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-morpholinyl)amino]pyrimido[5,4-d]pyrimidine; (e) 4-[(3-chloro-4-fluorophenyl)amino]-6-(4-picolylamino)pyrimido[5,4-d]pyrimidine; (f) 4-[(3-chloro-4-fluorophenyl)amino]-6-[1-trifluoroacetyl-4-piperidinylamino]pyrimido[5,4-d]pyrimidine; (g) 4-[(3-chloro-4-fluorophenyl)amino]-6-(endo-tropinylamino)pyrimido[5,4-d]pyrimidine; and, (h) 4-[(3-chloro-4-fluorophenyl)amino]-6-(exo-tropinylamino)pyrimido[5,4-d]pyrimidine.

Pyrimido[5,4]-dipyrimidines, pharmaceuticals containing them, their use and processes for the preparation thereof

Pyrimido[5,4-d]pyrimidines of the general formula [Figure] which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of disorders, in particular of oncoses, and their preparation. Exemplary compounds are: 4-[(3-Chloro-4-fluorophenyl)amino]-6-[1-methyl-4-piperidinylamino]pyrimido[5,4-d]pyrimidine, and 4-[(3-Chloro-4-fluorophenyl)amino]-6-[trans-4-dimethyl-aminocycohexylamino]pyrimido[5,4-d]pyrimidine.